SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation

STRO

Related stories